Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphoma

Limat, Samuel; Demesmay, K.; Voillat, Laurent; Bernard, Yvette; Deconinck, Eric; Brion, Annie; Sabbah, Anni Rebibo; Woronoff‐Lemsi, M.‐C.; Cahn, Jean‐Yves

doi:10.1093/annonc/mdg070

Cited by 125 publications

(112 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there were no instances of symptomatic cardiac failure, 3 of the 6 study participants experienced asymptomatic decreases in LVEF. 30 A similar onset threshold for doxorubicin dose (200 mg/m 2 ) was observed in a multivariate analysis of the relationship between CHOP and cardiotoxicity in patients with aggressive NHL. 31 The exact mechanisms underlying doxorubicin-and bevacizumab-induced cardiotoxicity are not known.…”

Section: Discussionsupporting

confidence: 55%

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 55%

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

et al. 2014

View full text Add to dashboard Cite

show abstract

“…One hundred thirty cycles were evaluated. The median number of cycles administered per patient was 6 (range, [1][2][3][4][5][6][7][8]. No treatment-related deaths occurred.…”

Section: Da-poch-r For Elderly Dlbcl Patients/musolino Et Almentioning

confidence: 99%

“…5 Higher treatment-related mortality has also been reported in older patients using the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, 6,7 and several recent studies have shown that anthracycline-related cardiotoxicity is more frequent in this group of patients. 8,9 These findings have often led to arbitrary dose reductions or use of less-aggressive therapy, which may reduce the possibility of cure.…”

mentioning

confidence: 99%

Activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma

Musolino

Boggiani

Panebianco

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: This study was designed to assess the activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab (DA-POCH-R) in elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma (DLBCL). METHODS: From April 2006 to November 2009, 23 patients, aged !70 years, with an age-adjusted International Prognostic Index (IPI) of 2 or 3, were enrolled. Only patients with left ventricular ejection fraction (LVEF) !50% were allowed. The DA-POCH-R regimen was administered every 3 weeks for a minimum of 6 and a maximum of 8 cycles. RESULTS: Median patient age was 77 years (range, 70-90 years); 83% of patients had Ann Arbor stage III to IV disease. Median LVEF at baseline was 62%. Four (17%) patients had a history of abnormal cardiovascular conditions. Twenty-one (91%) patients were evaluable for response. The overall response rate was 90%, with a complete response rate of 57%. The 3-year overall survival and event-free survival rates were 56% and 54%, respectively. Neutropenia (48%) was the most frequent grade 3 to 4 adverse event (AE); no grade 3 to 4 cardiac AEs were observed. CONCLUSIONS: DA-POCH-R was an active and safe combination therapy for patients aged !70 years with poor-prognostic untreated DLBCL. This regimen was a reasonable alternative for elderly patients who were not considered to tolerate standard R-CHOP treatment. Cancer 2011;117:964-73.

show abstract

“…These facts indicate that other age-related medical conditions such as cardiovascular disease and the development of other malignancies are important. Age above 50 years is a risk factor for developing anthracycline-mediated cardiotoxicity [18]. This fact could contribute to the higher rate of death without lymphoma in older patients.…”

Section: Discussionmentioning

confidence: 99%

Factors predicting long‐term survival in low‐risk diffuse large B‐cell lymphoma

Møller¹,

Pedersen²,

Christensen³

2003

American J Hematol

View full text Add to dashboard Cite

The International Prognostic Index (IPI) is widely used for risk stratification of patients with diffuse large B-cell lymphoma (DLBCL). However, even among patients with low-risk disease, according to the IPI a substantial proportion of patients ultimately succumb to their disease. Using mature population-based data from the Danish Lymphoma Group, we analyzed if prognostic clinical pretreatment factors could be identified in patients with lowrisk DLBCL. One hundred seventy-seven patients, all with a prognostic profile as favorable as possible according to the IPI and treated with anthracycline-based combination chemotherapy (92%) or loco-regional radiotherapy/surgery (8%) with curative intent were included. The median age was 50 years and 170 achieved complete remission. The median follow-up time was 11 years. Twenty-six patients relapsed, with a median time to relapse of 12.1 months. Overall survival at 5 years and 10 years was 85% and 75%, respectively. Stage II was associated with poor response to treatment (P = 0.044). In a multivariate analysis, Stage II (P = 0.001) and age >50 years (P = 0.043) were independently associated with poor outcome. Patients without these adverse factors had an excellent prognosis, with a survival at 5 and 15 years of 90% and 80%, respectively. In contrast, patients with both adverse factors had poor outcome, with survival at 5 and 15 years of 70% and 29%, respectively (P < 0.001). The present data suggest that risk stratification of DLBCL patients with a favorable IPI score can be improved by the simple use of two clinical pretreatment factors. Am. J.

show abstract

Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphoma

Cited by 125 publications

References 29 publications

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

Activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma

Factors predicting long‐term survival in low‐risk diffuse large B‐cell lymphoma

Contact Info

Product

Resources

About